Bedfordshire and Luton Joint Formulary Formulary

Formulary items found

Status	Description	Section
RED	Rituximab Truxima^®	Musculoskeletal and joint diseases, Cytokine modulators, 10.01.03
RED	Rituximab Rixathon^®Truxima^®	Malignant disease and immunosuppression, Anti-lymphocyte monoclonal antibodies, 08.02.03
	Rituximab	Nutrition and blood, Drugs used in autoimmune thrombocytopenic purpura, 09.01.04
RED	Rituximab Truxima^®	Nutrition and blood, Drugs used in hypoplastic, haemolytic, and renal anaemias and in sickle cell disease, 09.01.03

Links found

Clinical Commissioning Policy; Rituximab and eculizumab for the prevention and management of delayed haemolytic transfusion reactions and hyperhaemolysis in patients with haemoglobinopathies [URN 1821] [200602P]
NICE TA 649 Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
NICE TA110: Follicular lymphoma - rituximab Non-Hodgkin's lymphoma - rituximab
NICE TA193: Leukaemia (chronic lymphocytic, relapsed) - rituximab
NICE TA226: Lymphoma (follicular non-Hodgkin’s) - rituximab
NICE TA243: Follicular lymphoma - rituximab (review)
NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
NICE TA627: Lenalidomide with rituximab for previously treated follicular lymphoma
NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma